Dicerna pushed up price and contacted other suitors before making deal with Novo Nordisk

Novo Nordisk wasn't alone in expressing interest in acquiring biotech business Dicerna, but after a bidding war, the Danish pharmaceutical company's offer was the most economically attractive, documents reveal.

Photo: Valdemar Ren

When the hammer came down, Novo Nordisk's final bid for US-based Dicerna far exceeded its initial offer.

This is evident in documents publicized Wednesday evening, revealing the internal negotiations between the two companies, which also involved other would-be suitors.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs